EMEA-002399-PIP01-18

Key facts

Active substance
Bulevirtide
Therapeutic area
Infectious diseases
Decision number
P/0296/2019
PIP number
EMEA-002399-PIP01-18
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of chronic hepatitis D infection
Route(s) of administration
Subcutaneous use
Contact for public enquiries
MYR GmbH

E-mail: alexandrov@myr-pharma.com
Tel. +49 6172 6816565

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating